Physician profile
John R Fleming
NPI 1366448771
$1,854.89
in general payments reported to CMS, 2019-2025
23 companies · $274 in 2025
The $274 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $287 · 2021: $443 · 2022: $204 · 2023: $181 · 2024: $274 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $729.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $307.72 | 2020-2025 | Jardiance, Zepbound, Mounjaro |
| Pfizer INC. | $194.99 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $180.30 | 2019-2022 | |
| Abbott Laboratories | $172.23 | 2021-2025 | Freestyle Libre 3 |
| Abbvie INC. | $159.72 | 2021-2025 | |
| Novo Nordisk INC | $137.06 | 2019-2022 | |
| Eisai INC. | $128.65 | 2020-2021 | |
| Amgen INC. | $125.93 | 2021-2025 | Repatha, Otezla, Repatha |
| Phathom Pharmaceuticals, INC. | $124.07 | 2024-2025 | Voquezna |
| Philips North America LLC | $38.57 | 2025 | Extended Holter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.24 | 2024-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals Lp | $35.52 | 2020-2022 | |
| Astellas Pharma US INC | $29.61 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $29.50 | 2022-2023 | Quviviq |
| Dexcom, INC. | $24.97 | 2025 | Dexcom G6 Transmitter |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $22.01 | 2022 | |
| Medtronic, INC. | $19.15 | 2023 | Intellis Adaptivestim |
| Seqirus USA INC | $17.58 | 2024 | Fluad, Flucelvax |
| Vertiflex, INC. | $15.62 | 2019 | |
| Glaxosmithkline, LLC. | $15.22 | 2020 | |
| Daiichi Sankyo INC. | $14.40 | 2020 | |
| Smith+Nephew, INC. | $14.27 | 2022 | |
| Allergan, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fleming listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.